Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grey Wolf HealthTSXV:WOLF 52 3-Year ROIIC % is 13.11 as of Dec. 2025, which is 18% above its 10-year median of 11.12. GuruFocus rates TSXV:WOLF with a GF Score™ of 52/100 and a GF Value™ of C$1.10 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 947 Drug Manufacturers companies, Grey Wolf Health ranks better than 63.89% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Grey Wolf Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 13.11%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Grey Wolf Health's 3-Year ROIIC % or its related term are showing as below:
TSXV:WOLF's 3-Year ROIIC % is ranked better than 63.89% of 947
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs TSXV:WOLF: 13.11
Grey Wolf Health (TSXV:WOLF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Grey Wolf Health 3-Year ROIIC % Related Terms
Grey Wolf Health 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Grey Wolf Health's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:WOLF vs ROL, SCI, FTDR: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grey Wolf Health's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grey Wolf Health 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grey Wolf Health's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Grey Wolf Health's 3-Year ROIIC % falls into.
Grey Wolf Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 2.8281347 (Dec. 2025) - -0.356 (Dec. 2022) )
/
( 52.992 (Dec. 2025) - 28.696 (Dec. 2022) )
=
3.1841347
/
24.296
=
13.11%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Grey Wolf Health (TSXV:WOLF) has a 3-Year ROIIC % of 13.11 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Grey Wolf Health and its competitors. This is 18% above median its historical median of 11.12. Over the past decade, Grey Wolf Health's 3-Year ROIIC % has ranged from 9.12 to 13.11. According to the industry distribution chart, Grey Wolf Health ranks #342 out of 947 companies in the Drug Manufacturers industry, placing it in the top 36.1%.
Is Grey Wolf Health's 3-Year ROIIC % too high?
Grey Wolf Health's current 3-Year ROIIC % of 13.11 is 18% above median its 10-year median of 11.12. Over the past 10 years, this metric has ranged from a low of 9.12 to a high of 13.11. The Drug Manufacturers industry median 3-Year ROIIC % is 3.70. Grey Wolf Health's value of 13.11 is 254.3% above this industry median. Based on the distribution chart, Grey Wolf Health ranks #342 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grey Wolf Health has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Grey Wolf Health's 3-Year ROIIC % compare to ROL and SCI?
According to the Drug Manufacturers industry distribution chart, Grey Wolf Health ranks #342 out of 947 companies for 3-Year ROIIC %. This puts Grey Wolf Health in the upper half of its industry. The industry median 3-Year ROIIC % is 3.70. Grey Wolf Health's value of 13.11 is 254.3% above this benchmark. Historically, Grey Wolf Health's own 3-Year ROIIC % has ranged from 9.12 to 13.11 over the past decade. While the company's 10-year median is 11.12 vs. the industry median of 3.70, Grey Wolf Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.70, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grey Wolf Health's current 3-Year ROIIC % of 13.11 is 254.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Grey Wolf Health and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grey Wolf Health's current 3-Year ROIIC % is 13.11, which is 18% above median its own 10-year median of 11.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grey Wolf Health stock overvalued right now?
Based on GuruFocus' analysis, Grey Wolf Health (TSXV:WOLF) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.10, compared to a current price of C$1.68 — trading 52.7% above its estimated fair value. The current 3-Year ROIIC % is 13.11, which is 18% above median its 10-year median of 11.12 and 254.3% above the Drug Manufacturers industry median of 3.70. Grey Wolf Health's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Grey Wolf Health (TSXV:WOLF), the current 3-Year ROIIC % is 13.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grey Wolf Health (TSXV:WOLF) Overvalued in 2026?
Based on GuruFocus' analysis, Grey Wolf Health stock appears to be overvalued.
The current stock price of C$1.68 is trading 52.7% above its estimated GF Value™ of C$1.10.
GuruFocus considers Grey Wolf Health to be Significantly Overvalued.
Key valuation signals for TSXV:WOLF:
3-Year ROIIC %: 13.11 (18% above median its 10-year median of 11.12)
GF Value™: C$1.10 vs. price of C$1.68 (52.7% above fair value)
Industry Position: 254.3% above the Drug Manufacturers median (#342 of 947)
No single metric tells the full story. See the TSXV:WOLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grey Wolf Animal Health Corp focuses on sourcing, in-licensing, acquiring, and compounding branded and generic products for sale in both animal and human health markets in Canada. The Company operates through two reportable segments: the Animal Health segment, which involves the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics across Canada; and the Pharmacy segment, which generates the majority of revenue and focuses on compounding pharmaceuticals for both human and animal health markets.
52GF Score
Get the complete analysis for TSXV:WOLF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WOLF has been successfully added to your 
